Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:AIMD

Ainos Q3 2024 Earnings Report

Ainos logo
$1.42 -0.03 (-2.07%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

Ainos EPS Results

Actual EPS
-$1.65
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ainos Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ainos Announcement Details

Quarter
Q3 2024
Date
11/6/2024
Time
N/A
Conference Call Date
Tuesday, November 5, 2024
Conference Call Time
6:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Ainos' Q3 2024 Quarterly reportQuarterly report
(10-Q)

Ainos Earnings Headlines

Ainos, Inc.: Ainos Launches Atmosphere Engine, Extending Physical AI from Environmental Sensing to Active Environmental Management
August 19, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69353610-ainos-inc-ainos-launches-atmosphere-engine-extending-physical-ai-from-environmental-sensing-to-active-environmental-management-200.htm
Ainos Unveils Next-Generation AI Nose, Advancing the Infrastructure for Chemical Intelligence
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/technology/ai/articles/ainos-unveils-next-generation-ai-130000100.html
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answer to a multi-variable problem. Withdrawal sequencing, sequence-of-returns risk, Roth conversion timing, and legacy goals can all shift your real number significantly. Research from Vanguard suggests advisor best practices - covering allocation, rebalancing, tax management, and behavioral coaching - may add roughly 3% in net annual return potential. Morningstar's 2025 data shows the average investor return gap is 1.2% per year due to mistimed buying and selling. Get matched with a fiduciary advisor in your area at no cost and with no obligation to hire.tc pixel
August 26 at 1:00 AM  |  SmartAsset (Ad)
Ainos, Inc.: Ainos Surpasses 878 Million Real-World Data Points, Up 43% in 23 Days as 1,400-System AI Nose Semiconductor Deployment Advances
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69304238-ainos-inc-ainos-surpasses-878-million-real-world-data-points-up-43-in-23-days-as-1-400-system-ai-nose-semiconductor-deployment-advances-200.htm
AIMD: Ainos is Building an AI Platform Around Digital Scent
August 5, 2026  |  msn.comhttps://www.msn.com/en-us/technology/artificial-intelligence/aimd-ainos-is-building-an-ai-platform-around-digital-scent/ar-AA29slLq
Interview with Jack Lu, Head of Corporate Development of Ainos, Inc.
June 29, 2026  |  msn.comhttps://www.msn.com/en-us/news/technology/interview-with-jack-lu-head-of-corporate-development-of-ainos-inc/ar-AA26NOQj
See More Ainos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ainos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ainos and other key companies, straight to your email.

About Ainos

Ainos (NASDAQ:AIMD) (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format. AI‐401 is engineered to target airway inflammation in conditions such as cystic fibrosis and other chronic respiratory diseases. In preclinical studies, the formulation demonstrated favorable pulmonary deposition and sustained release, and it has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of cystic fibrosis.

In addition to AI‐401, Ainos is exploring the application of its dry powder inhalation technology for other anti‐inflammatory and anti‐infective agents, with the goal of expanding its pipeline into multiple respiratory indications. The company collaborates with contract development and manufacturing organizations (CDMOs) to advance product candidates through formulation optimization, toxicology assessments and early clinical trials.

Founded in the United States, Ainos is headquartered in Philadelphia and serves patients and healthcare providers primarily in North America and Europe. The company’s management team comprises executives with extensive experience in respiratory drug development, regulatory affairs and commercial strategy. Ainos aims to leverage its inhalation platform to bring novel pulmonary therapies to market and address unmet medical needs in chronic lung disease.

View Ainos Profile
Earnings Tools